Philippe et al., 2021 - Google Patents

Angler peptides: macrocyclic conjugates inhibit p53: MDM2/X interactions and activate apoptosis in cancer cells

Philippe et al., 2021

View PDF
Document ID
537310712022059442
Author
Philippe G
Mittermeier A
Lawrence N
Huang Y
Condon N
Loewer A
Craik D
Henriques S
Publication year
Publication venue
ACS Chemical Biology

External Links

Snippet

Peptides are being developed as targeted anticancer drugs to modulate cytosolic protein– protein interactions involved in cancer progression. However, their use as therapeutics is often limited by their low cell membrane permeation and/or inability to reach cytosolic …
Continue reading at espace.library.uq.edu.au (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Similar Documents

Publication Publication Date Title
Philippe et al. Angler peptides: macrocyclic conjugates inhibit p53: MDM2/X interactions and activate apoptosis in cancer cells
Vinogradov et al. Macrocyclic peptides as drug candidates: recent progress and remaining challenges
Philippe et al. Converting peptides into drugs targeting intracellular protein–protein interactions
Owens et al. MOrPH-PhD: an integrated phage display platform for the discovery of functional genetically encoded peptide macrocycles
Dougherty et al. Understanding cell penetration of cyclic peptides
Qian et al. Efficient delivery of cyclic peptides into mammalian cells with short sequence motifs
Wolfe et al. Machine learning to predict cell-penetrating peptides for antisense delivery
Udugamasooriya et al. A peptoid “antibody surrogate” that antagonizes VEGF receptor 2 activity
Cromm et al. Protease-resistant and cell-permeable double-stapled peptides targeting the Rab8a GTPase
Schröder et al. Peptoidic amino-and guanidinium-carrier systems: targeted drug delivery into the cell cytosol or the nucleus
Trinh et al. Discovery of a direct Ras inhibitor by screening a combinatorial library of cell-permeable bicyclic peptides
Qian et al. Early endosomal escape of a cyclic cell-penetrating peptide allows effective cytosolic cargo delivery
Soudy et al. Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells
Sakagami et al. Importance of net hydrophobicity in the cellular uptake of all-hydrocarbon stapled peptides
McGuire et al. Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer
Dietrich et al. Peptides as drugs: from screening to application
Meng et al. CXC-mediated cellular uptake of miniproteins: forsaking “arginine magic”
EP2800759B1 (en) Binding agents to intracellular target molecules
Salim et al. Development of a cell-permeable cyclic peptidyl inhibitor against the Keap1–Nrf2 interaction
Philippe et al. Cell membrane composition drives selectivity and toxicity of designed cyclic helix–loop–helix peptides with cell penetrating and tumor suppressor properties
JP2012505929A (en) Bidentate peptide binder
Anananuchatkul et al. Construction of a stapled α-helix peptide library displayed on phage for the screening of galectin-3-binding peptide ligands
Joseph et al. Synthesis, characterization, and biological activity of poly (arginine)‐derived cancer‐targeting peptides in HepG2 liver cancer cells
Ngambenjawong et al. Engineering an affinity-enhanced peptide through optimization of cyclization chemistry
Díaz‐Perlas et al. Phage display as a tool to discover blood–brain barrier (BBB)‐shuttle peptides: panning against a human BBB cellular model